We are live on
!
Find out more
TSC
Two Seas Capital Portfolio holdings
AUM
$7.15B
1-Year Est. Return
169.27%
This Fund
S&P 500
This Quarter
Est. Return
+3.11%
1 Year Est. Return
+169.27%
3 Year Est. Return
+279.82%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$497M
AUM Growth
+$39.9M
(+8.7%)
Cap. Flow
+$29M
Cap. Flow
% of AUM
5.82%
Top 10 Holdings %
Top 10 Hldgs %
98.79%
Holding
17
New
3
Increased
5
Reduced
2
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
3M
MMM
|
+$13.3M |
| 2 |
Immunovant
IMVT
|
+$9.66M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$6.84M |
| 4 |
Sonos
SONO
|
+$3.49M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ROIVW
Roivant Sciences Ltd. Warrant
ROIVW
|
+$2.73M |
| 2 |
OSG
Octave Specialty Group
OSG
|
+$2.67M |
| 3 |
Hertz
HTZ
|
+$1.62M |
| 4 |
MNK
Mallinckrodt plc
MNK
|
+$691K |
| 5 |
Arcutis Biotherapeutics
ARQT
|
+$573K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.37% |
| 2 | Industrials | 2.66% |
| 3 | Communication Services | 2.18% |
| 4 | Technology | 1.05% |
| 5 | Materials | 1.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Indivior Pharmaceuticals
INDV
$4.58B
| $315M | 63.41% |
13,670,312
+1,393
| +0% | +$31.8K |
|
2
Roivant Sciences
ROIV
$25B
| $92.4M | 18.59% |
7,915,232
+5,641
| +0.1% | +$63.8K |
|
3
Arbutus Biopharma
ABUS
$913M
| $16.8M | 3.38% |
8,280,818
| – | – |
|
|
4
Immunovant
IMVT
$8.06B
| $16.4M | 3.3% |
+427,256
| New | +$9.66M |
|
|
5
3M
MMM
$93.9B
| $12.2M | 2.45% |
+155,480
| New | +$13.3M |
|
|
6
Meta Platforms (Facebook)
META
$1.5T
| $10.9M | 2.18% |
36,175
+6,172
| +21% | +$1.86M |
|
|
ESPR
7
DELISTED
Esperion Therapeutics
ESPR
| $7.52M | 1.51% |
7,672,170
+4,730,298
| +161% | +$6.84M |
|
|
8
Sonos
SONO
$1.88B
| $5.24M | 1.05% |
406,172
+235,000
| +137% | +$3.49M |
|
9
Odyssey Marine Exploration
OMEX
$43.5M
| $5.13M | 1.03% |
1,371,874
| – | – |
|
|
10
CALL
Immunovant
IMVT
$8.06B
| $3.32M | 0.67% |
+86,600
| New | +$1.96M |
|
|
11
Hertz
HTZ
$493M
| $1.07M | 0.21% |
87,188
-96,721
| -53% | -$1.62M |
|
|
12
Arcutis Biotherapeutics
ARQT
$3.39B
| $875K | 0.18% |
164,807
-67,394
| -29% | -$573K |
|
|
HTZWW
13
Hertz Global Holdings Warrants
HTZWW
$67.7M
| $756K | 0.15% |
123,494
| – | – |
|
|
OSG
14
Octave Specialty Group
OSG
$256M
| – | – |
-187,568
| Closed | -$2.67M |
|
|
ROIVW
15
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
| – | – |
-1,100,662
| Closed | -$2.73M |
|
|
MNK
16
DELISTED
Mallinckrodt plc
MNK
| – | – |
-585,602
| Closed | -$691K |
|
Similar funds
UB
FPA
FPP
SC
CFG
DS
MNA
NAMA
Two Seas Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Two Seas Capital held 17 positions worth $497M, up 8.7% from $457M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Two Seas Capital deployed $29M of net new capital in Q3 2023, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was 3M: 155,480 shares worth $12.2M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier, followed by Industrials and Communication Services.
On the sell side, the largest reduction was Hertz, an estimated $1.62M trimmed.
- Two Seas Capital's largest Q3 2023 buy was 3M: 155,480 shares worth $12.2M.
- Two Seas Capital added most to Esperion Therapeutics in Q3 2023, an estimated $6.84M increase.
- Two Seas Capital's biggest Q3 2023 reduction was Hertz, cutting an estimated $1.62M.
- Two Seas Capital fully exited Roivant Sciences Ltd. Warrant in Q3 2023, selling an estimated $2.73M.
- Two Seas Capital's ten largest holdings make up 99% of its $497M portfolio in Q3 2023.
- Two Seas Capital opened 3 new positions and closed 3 in Q3 2023.
- Two Seas Capital's portfolio value rose 8.7% quarter-over-quarter to $497M.
Based on Two Seas Capital's 13F filing for Q3 2023, filed 14 Nov 2023.